5H,6H,7H,8H-Imidazo[1,5-A]pyrazin-8-one | 951626-36-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5H,6H,7H,8H-Imidazo[1,5-A]pyrazin-8-one
• 英文别名: 6,7-dihydro-5H-imidazo[1,5-a]pyrazin-8-one
• CAS: 951626-36-1
• 化学式: C₆H₇N₃O
• mdl: MFCD09832033
• 分子量: 137.14
• InChiKey: WXWQYMIMMRLBAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-(2-tert-butoxycarbonylaminoethyl)-3H-imidazole-4-carboxylic acid methyl ester 在 盐酸 、 sodium carbonate 作用下， 以 甲醇 、 二氯甲烷 、 四氢呋喃 、 水 为溶剂， 以0.3 g的产率得到5H,6H,7H,8H-Imidazo[1,5-A]pyrazin-8-one
  参考文献：
  名称：

  HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

  摘要：

  The present invention relates to heteroaromatic compounds of formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof as antagonist at serotonin 5-HT2Areceptor and agonist at serotonin 5-HT1Areceptor. The present invention also describes methods of making such compounds, pharmaceutical compositions comprising such compounds, and their use in the treatment of CNS disorders.

  公开号：

  WO2024042480A1

文献信息

• [EN] 6,7- DIHYDROIMIDAZO [1,5-A] PYRAZIN-8 (5H) - ONE DERIVATIVES AS PROTEIN KINASE MODULATORS<br/>[FR] DÉRIVÉS DE 6,7-DIHYDROIMIDAZO[1,5-A]PYRAZIN-8(5H)-ONE COMME MODULATEURS DE PROTÉINES KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2011092120A1

  公开（公告）日：2011-08-04

  There are provided 3,5-disubstituted derivatives of 6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one compounds of formula (I) or a pharmaceutically acceptable salt thereof as defined in the present specification, which modulate the activity of protein kinases. The compounds are therefore useful in treating diseases caused by dysregulated protein kinase activity. In particular, such diseases to be treated with a compound of formula (I) of the present invention is one caused by and/or associated with disregulated protein kinase activity selected from the group consisting of cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders. The present invention also relates to processes for preparing the compounds of formula (I), combinatorial libraries thereof, pharmaceutical compositions comprising them, and methods of treating diseases utilizing pharmaceutical compositions comprising a compound of formula (I).

  提供了6,7-二氢咪唑[1,5-a]吡嗪-8(5H)-酮化合物的3,5-二取代衍生物，其化学式为(I)，或其药学上可接受的盐，如本说明书中所定义，这些衍生物调节蛋白激酶的活性。因此，这些化合物在治疗由蛋白激酶活性失调引起的疾病中很有用。特别是，本发明的化合物的化学式(I)用于治疗由蛋白激酶活性失调引起和/或与之相关的疾病，包括癌症、病毒感染、预防HIV感染者中艾滋病发展、细胞增殖紊乱疾病、自身免疫和神经退行性疾病。本发明还涉及制备化学式(I)化合物的方法、其组合库、包含它们的药物组合物，以及利用包含化学式(I)化合物的药物组合物治疗疾病的方法。
• 6,7- DIHYDROIMIDAZO [1,5-A]PYRAZIN-8 (5H) - ONE DERIVATIVES AS PROTEIN KINASE MODULATORS
  申请人：Nerviano Medical Sciences S.r.l.

  公开号：EP2528918A1

  公开（公告）日：2012-12-05
• 6,7-DIHYDROIMIDAZO[1,5-A]PYRAZIN-8(5H)-ONE DERIVATIVES AS PROTEIN KINASE MODULATORS
  申请人：Nerviano Medical Sciences S.r.l.

  公开号：EP2528918B1

  公开（公告）日：2014-09-10
• US8772279B2
  申请人：——

  公开号：US8772279B2

  公开（公告）日：2014-07-08